ABSTRACT
Moxifloxacin is a recent fluoroquinolone with an antibacterial spectrum encompassing both aerobic Gram-negative and Gram-positive strains, as well as anaerobic bacteria. In this study the activity of moxifloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Moraxella catarrhalis, Haemophilus influenzae, Escherichia coli, Proteus mirabilis and Pseudomonas aeruginosa, and effects of subinhibitory concentrations on bacterial morphology and adhesion properties were compared with those of amoxicillin, clarithromycin and ceftriaxone. The in vitro activity of moxifloxacin against Gram-positive and Gram-negative pathogens was equal to or better than that of comparators. Subinhibitory concentrations of moxifloxacin significantly affected bacterial morphology of S. pneumoniae, M. catarrhalis, H. influenzae and P. aeruginosa, leading to formation of spherical forms and filaments. Moreover, bacterial adhesion to buccal cells and fibroblasts was reduced after treatment with 1/4 and 1/8 X MIC of moxifloxacin. In conclusion, subinhibitory concentrations of moxifloxacin remarkably interfere with some bacterial pathogenic factors, thereby contributing to its antimicrobial activity.
Subject(s)
Aza Compounds/pharmacology , Gram-Negative Bacteria/drug effects , Gram-Negative Bacteria/pathogenicity , Gram-Positive Bacteria/drug effects , Gram-Positive Bacteria/pathogenicity , Quinolines/pharmacology , Amoxicillin/pharmacology , Anti-Bacterial Agents/pharmacology , Ceftriaxone/pharmacology , Clarithromycin/pharmacology , Dose-Response Relationship, Drug , Fluoroquinolones , Microbial Sensitivity Tests , MoxifloxacinABSTRACT
Thiamphenicol-glycinate-acetylcysteinate (TGA; CAS 20192-91-0) is widely used for the treatment of infections of varied aetiology. The aim of this study was to compare the antibacterial activity of thiamphenicol-glycinate (TG; CAS 15318-45-3), TGA, amoxicillin (CAS 61336-70-7) plus clavulanic acid (CAS 58001-44-8), azithromycin (CAS 83905-01-5) and ceftriaxone (CAS 104376-79-6). Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined against Staphylococcus aureus, Klebsiella pneumoniae, Streptococcus pyogenes, Streptococcus pneumoniae, Moraxella catarrhalis and Haemophilus influenzae according to the National Committee for Clinical Laboratory Standards (NCCLS) methods. The effects of changes in assay conditions were also examined. The activity of TG and TGA was similar to that of amoxicillin plus clavulanic acid, with the exception of methicillin resistant S. aureus. Azithromycin and ceftriaxone were characterised by a limited activity against gram-positive cocci and methicillin resistant and cefinase-positive S. aureus, respectively. TG and TGA are characterized by a wide spectrum of activity, comparable to that of recent commercialized antibiotics for treatment of respiratory tract infections.
Subject(s)
Acetylcysteine/pharmacology , Bacteria/drug effects , Respiratory Tract Diseases/microbiology , Thiamphenicol/pharmacology , Cations, Divalent/pharmacology , Culture Media , Drug Combinations , Hydrogen-Ion Concentration , Microbial Sensitivity Tests , Thiamphenicol/analogs & derivativesABSTRACT
In this study the antibacterial and antifungal properties of propolis, a natural product of bees, have been investigated against different pathogens. Minimum inhibitory concentrations (MICs) and minimum bactericidal concentrations (MBCs) were determined according to NCCLS standards on 320 strains including Staphylococcus aureus, Group A beta-hemolytic streptococci, Streptococcus pneumoniae, Moraxella catarrhalis, Haemophilus influenzae, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, Pseudomonas aeruginosa and Candida albicans. Time-kill curves were assessed for susceptible microorganisms, testing 0, 0.5, 1, 2, 4 x MIC for propolis, by counting viable bacteria after 0, 3, 6, 24 hours and viable yeasts after 0, 3, 6, 24 and 48 hours. Propolis showed good antimicrobial activity against most of the isolates, particularly S. pneumoniae, H. influenzae and M. catarrhalis, but not against Enterobacteriaceae. Time-kill curves demonstrated bacteriostatic rather than bactericidal activity of propolis, the latter being evident only at high concentrations.
Subject(s)
Propolis/pharmacology , Staphylococcus aureus/drug effects , Candida albicans/drug effects , Escherichia coli/drug effects , Humans , Microbial Sensitivity Tests , Moraxella catarrhalis/drug effects , Streptococcus pneumoniae/drug effects , Time FactorsSubject(s)
Drug Resistance, Microbial/genetics , Gram-Negative Bacteria/genetics , Gram-Negative Bacterial Infections/microbiology , Gram-Negative Bacteria/drug effects , Gram-Negative Bacterial Infections/drug therapy , Gram-Negative Bacterial Infections/epidemiology , Humans , Molecular Epidemiology , Outpatients , Sentinel SurveillanceABSTRACT
A new quantitative reverse transcription (RT)-PCR assay for human immunodeficiency virus type 1 (HIV-1) RNA (Abbott LCx HIV RNA Quantitative assay) has been compared with the Organon NucliSens assay on 521 retrospective samples obtained from HIV-1-positive patients monitored during highly active antiretroviral therapy, 79 of whom were assayed also by the Chiron Quantiplex 3.0 system and on characterized panels. The LCx system showed a moderate correlation (r = 0.795) and gave higher results than the NucliSens system on 245 of 327 concordant positive samples, with similar sensitivity. Correlation with Quantiplex system results was higher (r = 0.943). LCx reproducibility was very good; the procedure was simple, well controlled, and rapid (up to 48 results in 7 h). The HIV RNA quantitative assay on the LCx system is suitable for routine use.
Subject(s)
HIV Infections/drug therapy , HIV Seropositivity/drug therapy , HIV-1/isolation & purification , RNA, Viral/blood , Reagent Kits, Diagnostic , Reverse Transcriptase Polymerase Chain Reaction , Antiretroviral Therapy, Highly Active , HIV Infections/blood , HIV Seropositivity/blood , Humans , Polymerase Chain Reaction/methods , Regression Analysis , Reproducibility of Results , Retrospective Studies , Sensitivity and Specificity , Viral LoadABSTRACT
Corynebacterium minutissimum, known as the causative agent of erythrasma, has recently been reported as a clinically significant pathogen in the immunocompromised host. We report for the first time the possible involvement of a multidrug-resistant C. minutissimum strain in a costochondral abscess occurring in an HIV-infected patient.
Subject(s)
AIDS-Related Opportunistic Infections/drug therapy , Abscess/drug therapy , Corynebacterium Infections/complications , HIV Infections/complications , HIV-1 , AIDS-Related Opportunistic Infections/surgery , Abscess/microbiology , Abscess/surgery , Adult , Amikacin/therapeutic use , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Infective Agents/therapeutic use , Antibiotics, Antitubercular/therapeutic use , Ciprofloxacin/therapeutic use , Corynebacterium/classification , Corynebacterium/drug effects , Corynebacterium Infections/drug therapy , Corynebacterium Infections/surgery , Drug Resistance, Microbial , Drug Resistance, Multiple , Humans , Male , Penicillins/therapeutic use , Ribs/microbiology , Ribs/surgery , Rifampin/therapeutic use , Tomography, X-Ray Computed , Vancomycin/therapeutic useSubject(s)
Actinomycetales Infections/diagnosis , Foot Dermatoses/diagnosis , HIV Seropositivity/diagnosis , Mycetoma/diagnosis , Rhodococcus equi , Actinomycetales Infections/complications , Adult , Diagnosis, Differential , Female , Foot Dermatoses/complications , HIV Seropositivity/complications , Humans , Mycetoma/complicationsABSTRACT
We reviewed the cases of typhoid fever (3 cases) and non-typhoid salmonellosis (62 cases) diagnosed from 1987 to 1989 in the Laboratory of Clinical Chemistry and Microbiology of the 'L.Sacco' Hospital, Milan. Two cases of typhoid fever and 24 cases of non-typhoid salmonellosis occurred in patients without clinical symptoms of HIV infection. One case of typhoid fever and 38 cases of non-typhoid salmonellosis occurred in patients with clinical symptoms of HIV infection. In AIDS patients living in the Milan province the annual incidence of non-typhoid salmonellosis was estimated to be 100-fold greater than that observed in the general population. In patients with non-typhoid salmonellosis, bacteremias was found only in subjects with HIV disease (P = 0.0009). The frequency of bacteremia was higher in patients with AIDS than in patients with other manifestations of HIV disease (P = 0.0356). Finally, a significant difference between patients with and without HIV disease was found with regard to Salmonella serotypes distribution (P = 0.0196).